Serum Calcium May Have Negative Effect on Bone Mineral Density
Elevated calcium levels may lead to suboptimal growth of bone, according to the study’s findings.
General Rheumatology
Direct-Acting Antiviral Therapy Effective in Concomitant Hepatitis C Virus Infection, Rheumatic Diseases
Researchers assessed the effectiveness and safety of direct-acting antiviral therapy for patients with concomitant hepatitis C virus infection and rheumatic diseases, including rheumatoid arthritis.
Risk for Birth Defects Not Increased With Adalimumab
Adalimumab exposure in pregnancy does not increase the risk for birth defects.
Insufficient Evidence to Support Use of Medical Cannabis for Rheumatologic Conditions
There is insufficient evidence to support the use of medical cannabis or cannabis-related medications for the treatment of musculoskeletal and autoimmune disorders.
Interleukin Inhibitors Linked to Increased Infection, Cancer Risk in Rheumatologic Diseases
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
Interstitial Lung Disease Associated With More Muscle Mass, Less Bone Density Loss
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
Symptom-Based Stratification Reveals Pathobiologic Endotypes With Distinct Treatment Responses in Sjogren Syndrome
Researchers aimed to develop a stratification method to evaluate symptom prevalence and distinct treatment responses in patients with Sjogren syndrome.
DAIR Linked to High Readmission, Deep Surgical Site Infection of Prosthetic Joints
Polymicrobial prosthetic joint infections managed with surgical debridement, antibiotics and implant retention (DAIR) had high readmission rates and deep surgical site infections.
Hidradenitis Suppurativa Carries Heavy Comorbidity Burden
There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
Nintedanib Granted Breakthrough Therapy for Progressive Fibrosing Interstitial Lung Disease
The FDA has granted Breakthrough Therapy designation to nintedanib (Ofev; Boehringer Ingelheim) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Next post in General Rheumatology
